##fileformat=VCFv4.2
##fileDate=20210205
##reference=ftp://ftp.ncbi.nih.gov/genbank/genomes/Eukaryotes/vertebrates_mammals/Homo_sapiens/GRCh37/special_requests/GRCh37-lite.fa.gz
##source=CIViCpy_v1.1.3
##aboutURL=https://civicdb.org/help/evidence/overview
##INFO=<ID=GN,Number=1,Type=String,Description="HGNC Gene Symbol">
##INFO=<ID=VT,Number=1,Type=String,Description="CIViC Variant Name">
##INFO=<ID=CSQ,Number=.,Type=String,Description="Consequence annotations from CIViC. Format: Allele|Consequence|SYMBOL|Entrez Gene ID|Feature_type|Feature|HGVSc|HGVSp|CIViC Variant Name|CIViC Variant ID|CIViC Variant Aliases|CIViC HGVS|Allele Registry ID|ClinVar IDs|CIViC Variant Evidence Score|CIViC Entity Type|CIViC Entity ID|CIViC Entity URL|CIViC Entity Source|CIViC Entity Variant Origin|CIViC Entity Status|CIViC Entity Clinical Significance|CIViC Entity Direction|CIViC Entity Disease|CIViC Entity Drugs|CIViC Entity Drug Interaction Type|CIViC Evidence Phenotypes|CIViC Evidence Level|CIViC Evidence Rating|CIViC Assertion ACMG Codes|CIViC Assertion AMP Category|CIViC Assertion NCCN Guideline|CIVIC Assertion Regulatory Approval|CIVIC Assertion FDA Companion Test ">
#CHROM	POS	ID	REF	ALT	QUAL	FILTER	INFO
1	8073509	691	C	A	.	.	GN=ERRFI1;VT=E384*;CSQ=A|loss_of_function_variant&stop_gained|ERRFI1|54206|transcript|ENST00000377482.5|||E384*|691|E384X&GLU384TER|NC\x5F000001\x2E10\x3Ag\x2E8073509C\x3EA|CA338219584|NONE_FOUND|5.0|evidence|1724|https://civicdb.org/links/evidence/1724|24550739_(PubMed)|Somatic|accepted|Sensitivity/Response|Supports|Cholangiocarcinoma_(DOID_4947)|Erlotinib_(NCIt_ID_C65530)|||C|2|||||
1	11177096	609	C	A	.	.	GN=MTOR;VT=M2327I;CSQ=A|missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6981G>T||M2327I|609|MET2327ILE|ENST00000361445\x2E4\x3Ac\x2E6981G\x3ET&NC\x5F000001\x2E10\x3Ag\x2E11177096C\x3EA|CA338383476|NONE_FOUND|7.0|evidence|1544|https://civicdb.org/links/evidence/1544|27279227_(PubMed)|Somatic|accepted|Resistance|Supports|Breast_Cancer_(DOID_1612)|MTOR_Kinase_Inhibitor_AZD8055_(NCIt_ID_C78856)|||D|4|||||,A|missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6981G>T||M2327I|609|MET2327ILE|ENST00000361445\x2E4\x3Ac\x2E6981G\x3ET&NC\x5F000001\x2E10\x3Ag\x2E11177096C\x3EA|CA338383476|NONE_FOUND|7.0|evidence|1545|https://civicdb.org/links/evidence/1545|27279227_(PubMed)|Somatic|accepted|Resistance|Does_Not_Support|Breast_Cancer_(DOID_1612)|Sirolimus_(NCIt_ID_C1212)&RapaLink-1|Substitutes||D|3|||||
1	11184573	542	G	T	.	.	GN=MTOR;VT=S2215Y;CSQ=T|missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6644C>A||S2215Y|542|SER2215TYR|ENST00000361445\x2E4\x3Ac\x2E6644C\x3EA&NC\x5F000001\x2E10\x3Ag\x2E11184573G\x3ET&NM\x5F004958\x2E3\x3Ac\x2E6644C\x3EA&NP\x5F004949\x2E1\x3Ap\x2ESer2215Tyr|CA16602587|376129|2.0|evidence|1319|https://civicdb.org/links/evidence/1319|24631838_(PubMed)|Somatic|accepted|Sensitivity/Response|Supports|Endometrial_Adenocarcinoma_(DOID_2870)|Sirolimus_(NCIt_ID_C1212)|||D|2|||||
1	11184580	284	G	A	.	.	GN=MTOR;VT=P2213S;CSQ=A|gain_of_function_variant&missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6637C>T||P2213S|284|PRO2213SER|ENST00000361445\x2E4\x3Ac\x2E6637C\x3ET&NC\x5F000001\x2E10\x3Ag\x2E11184580G\x3EA&NM\x5F004958\x2E3\x3Ac\x2E6637C\x3ET&NP\x5F004949\x2E1\x3Ap\x2EPro2213Ser|CA16602798|376358|3.0|evidence|722|https://civicdb.org/links/evidence/722|26490311_(PubMed)|Somatic|accepted|Sensitivity/Response|Supports|Melanoma_(DOID_1909)|PI3K/BET_Inhibitor_LY294002_(NCIt_ID_C148229)&Capivasertib_(NCIt_ID_C102564)|Combination||D|3|||||
1	11187094	470	G	T	.	.	GN=MTOR;VT=F2108L;CSQ=T|missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6324C>A||F2108L|470|PHE2108LEU|ENST00000361445\x2E4\x3Ac\x2E6324C\x3EA&NC\x5F000001\x2E10\x3Ag\x2E11187094G\x3ET|CA338391533|NONE_FOUND|16.5|evidence|1110|https://civicdb.org/links/evidence/1110|25295501_(PubMed)|Somatic|accepted|Resistance|Supports|Thyroid_Gland_Carcinoma_(DOID_3963)|Everolimus_(NCIt_ID_C48387)|||C|5|||||,T|missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6324C>A||F2108L|470|PHE2108LEU|ENST00000361445\x2E4\x3Ac\x2E6324C\x3EA&NC\x5F000001\x2E10\x3Ag\x2E11187094G\x3ET|CA338391533|NONE_FOUND|16.5|evidence|1543|https://civicdb.org/links/evidence/1543|27279227_(PubMed)|Somatic|accepted|Resistance|Supports|Breast_Cancer_(DOID_1612)|Sirolimus_(NCIt_ID_C1212)|||D|4|||||
1	11187796	610	G	A	.	.	GN=MTOR;VT=A2034V;CSQ=A|missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6101C>T||A2034V|610|ALA2034VAL|ENST00000361445\x2E4\x3Ac\x2E6101C\x3ET&NC\x5F000001\x2E10\x3Ag\x2E11187796G\x3EA|CA338393920|NONE_FOUND|8.0|evidence|1547|https://civicdb.org/links/evidence/1547|27279227_(PubMed)|Somatic|accepted|Resistance|Supports|Breast_Cancer_(DOID_1612)|Sirolimus_(NCIt_ID_C1212)|||D|4|||||,A|missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.6101C>T||A2034V|610|ALA2034VAL|ENST00000361445\x2E4\x3Ac\x2E6101C\x3ET&NC\x5F000001\x2E10\x3Ag\x2E11187796G\x3EA|CA338393920|NONE_FOUND|8.0|evidence|1548|https://civicdb.org/links/evidence/1548|27279227_(PubMed)|Somatic|accepted|Resistance|Does_Not_Support|Breast_Cancer_(DOID_1612)|RapaLink-1&MTOR_Kinase_Inhibitor_AZD8055_(NCIt_ID_C78856)|Substitutes||D|4|||||
1	11188519	283	G	A	.	.	GN=MTOR;VT=H1968Y;CSQ=A|missense_variant&gain_of_function_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.5902C>T||H1968Y|283|HIS1968TYR|ENST00000361445\x2E4\x3Ac\x2E5902C\x3ET&NC\x5F000001\x2E10\x3Ag\x2E11188519G\x3EA&NM\x5F004958\x2E3\x3Ac\x2E5902C\x3ET&NP\x5F004949\x2E1\x3Ap\x2EHis1968Tyr|CA16602797|376357|3.0|evidence|713|https://civicdb.org/links/evidence/713|26490311_(PubMed)|Somatic|accepted|Sensitivity/Response|Supports|Melanoma_(DOID_1909)|Capivasertib_(NCIt_ID_C102564)&PI3K/BET_Inhibitor_LY294002_(NCIt_ID_C148229)|Substitutes||D|3|||||
1	11190804	544	C	T	.	.	GN=MTOR;VT=E1799K;CSQ=T|missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.5395G>A||E1799K|544|GLU1799LYS&RS863225264|NM\x5F004958\x2E3\x3Ac\x2E5395G\x3EA&NP\x5F004949\x2E1\x3Ap\x2EGlu1799Lys&NC\x5F000001\x2E10\x3Ag\x2E11190804C\x3ET&ENST00000361445\x2E4\x3Ac\x2E5395G\x3EA|CA279594|217823|2.0|evidence|1321|https://civicdb.org/links/evidence/1321|24631838_(PubMed)|Somatic|accepted|Sensitivity/Response|Supports|Clear_Cell_Renal_Cell_Carcinoma_(DOID_4467)|Sirolimus_(NCIt_ID_C1212)|||D|2|||||
1	11217230	543	C	T	.	.	GN=MTOR;VT=C1483Y;CSQ=T|missense_variant|MTOR|2475|transcript|ENST00000361445.4|ENST00000361445.4:c.4448G>A||C1483Y|543|CYS1483TYR|ENST00000361445\x2E4\x3Ac\x2E4448G\x3EA&NC\x5F000001\x2E10\x3Ag\x2E11217230C\x3ET&NM\x5F004958\x2E3\x3Ac\x2E4448G\x3EA&NP\x5F004949\x2E1\x3Ap\x2ECys1483Tyr|CA16602888|376453|2.0|evidence|1320|https://civicdb.org/links/evidence/1320|24631838_(PubMed)|Somatic|accepted|Sensitivity/Response|Supports|T-cell_Acute_Lymphoblastic_Leukemia_(DOID_5603)|Sirolimus_(NCIt_ID_C1212)|||D|2|||||
1	11856378	258	G	A	.	.	GN=MTHFR;VT=A222V;CSQ=A|missense_variant|MTHFR|4524|transcript|ENST00000376592.1|ENST00000376592.1:c.665G>A||A222V|258|RS1801133&C677T&ALA222VAL|NM\x5F005957\x2E4\x3Ac\x2E665C\x3ET&NP\x5F005948\x2E3\x3Ap\x2EAla222Val&ENST00000376592\x2E1\x3Ac\x2E665G\x3EA&NC\x5F000001\x2E10\x3Ag\x2E11856378G\x3EA|CA170990|3520|55.0|evidence|669|https://civicdb.org/links/evidence/669|18704422_(PubMed)|Rare_Germline|accepted|Sensitivity/Response|Supports|Stomach_Cancer_(DOID_10534)|Fluorouracil_(NCIt_ID_C505)|||B|3|||||,A|missense_variant|MTHFR|4524|transcript|ENST00000376592.1|ENST00000376592.1:c.665G>A||A222V|258|RS1801133&C677T&ALA222VAL|NM\x5F005957\x2E4\x3Ac\x2E665C\x3ET&NP\x5F005948\x2E3\x3Ap\x2EAla222Val&ENST00000376592\x2E1\x3Ac\x2E665G\x3EA&NC\x5F000001\x2E10\x3Ag\x2E11856378G\x3EA|CA170990|3520|55.0|evidence|1757|https://civicdb.org/links/evidence/1757|26693073_(PubMed)|Common_Germline|accepted|Sensitivity/Response|Supports|Rectum_Cancer_(DOID_1993)|Fluorouracil_(NCIt_ID_C505)|||B|4|||||,A|missense_variant|MTHFR|4524|transcript|ENST00000376592.1|ENST00000376592.1:c.665G>A||A222V|258|RS1801133&C677T&ALA222VAL|NM\x5F005957\x2E4\x3Ac\x2E665C\x3ET&NP\x5F005948\x2E3\x3Ap\x2EAla222Val&ENST00000376592\x2E1\x3Ac\x2E665G\x3EA&NC\x5F000001\x2E10\x3Ag\x2E11856378G\x3EA|CA170990|3520|55.0|evidence|1756|https://civicdb.org/links/evidence/1756|27819322_(PubMed)|Rare_Germline|accepted|Better_Outcome|Supports|Pancreatic_Cancer_(DOID_1793)||||B|4|||||
1	17350521	2411	G	GGCAGCTGGTGCT	.	.	GN=SDHB;VT=p.193_196dupSTSC_(c.577_588dupAGCACCAGCTGC);CSQ=GCAGCTGGTGCT|inframe_insertion|SDHB|6390|transcript|ENST00000375499.3|||p.193_196dupSTSC_(c.577_588dupAGCACCAGCTGC)|2411|C\x2E589\x5F600DUP|NM\x5F003000\x2E2\x3Ac\x2E577\x5F588dupAGCACCAGCTGC&NP\x5F002991\x2E2\x3Ap\x2E193\x5F196dupSTSC&NC\x5F000001\x2E10\x3Ag\x2E17350522\x5F17350533dup|CA658820851||5.0|evidence|6442|https://civicdb.org/links/evidence/6442|20193854_(PubMed)|Rare_Germline|accepted|Uncertain_Significance|Supports|Paraganglioma_(DOID_0050773)||||C|2|||||
1	27057658	1510	C	T	.	.	GN=ARID1A;VT=Q456*;CSQ=T|stop_gained|ARID1A|8289|transcript|ENST00000324856.7|ENST00000324856.7:c.1366C>T||Q456*|1510|Q73X|ENST00000324856\x2E7\x3Ac\x2E1366C\x3ET|CA339267901|NONE_FOUND|0.0|evidence|4487|https://civicdb.org/links/evidence/4487|27364904_(PubMed)|Somatic|accepted|Sensitivity/Response|Supports|Ovarian_Clear_Cell_Carcinoma_(DOID_0050934)|Dasatinib_(NCIt_ID_C38713)|||D|None|||||